nach oben

Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen

Erschienen in:

10.01.2020 | Originalien

Korreliert die Prävalenz der bisphosphonatassoziierten Kiefernekrosen mit der Einnahmedauer der Bisphosphonate bei Tumor- und Osteoporosepatienten?

Gesamtauswertung des Deutschen Kieferosteonekroseregisters

verfasst von: Cand. med. Dent. Niels Karberg, BA, Prof. Dr. med. Dieter Felsenberg

Erschienen in: Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die erste Veröffentlichung zum Thema der Osteonekrose des Kieferknochens (ONJ, „osteonecrosis of the jaw“) erfolgte 2003. Bei Tumor- und Osteoporosepatienten werden im Zuge ihrer Grunderkrankung Bisphosphonate appliziert. Dies geschieht bei Tumorpatienten zur Risikoreduktion der Entwicklung einer Knochenmetastasierung, bei Osteoporosepatienten zur Verringerung des Frakturrisikos. Trotz der geringen Wahrscheinlichkeit werden Nebenwirkungen in Form von Nekrosen nach Interventionen am Kieferknochen häufig von den behandelnden Ärzten erwartet. Nach Auswertung der Registerdaten konnte nicht festgestellt werden, dass die Länge der Einnahme mit der Prävalenz von ONJ korreliert. Die Lokalisationen der ONJ decken sich weitestgehend mit den Ergebnissen bisheriger Studien.

Vorheriger Artikel Protonenpumpeninhibitoren und Osteoporoserisiko

Nächster Artikel Kann eine Unterscheidung in verschiedene Patientensubgruppen die Therapie beim chronischen Kreuzschmerz verbessern?

Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117CrossRefPubMed

Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534CrossRefPubMed

Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ) (2004) Osteonekrose des Kiefers unter Bisphosphonaten. Dtsch Arztebl 101:A2203

Freyschmidt J (1980) Knochenerkrankungen im Erwachsenenalter. Springer, BerlinCrossRef

Akintoye SO, Lam T, Shi S et al (2006) Skeletal sitespecific characterization of orofacial and iliac crest human bone marrow stromal cells in same individuals. Bone 38:758–768CrossRefPubMed

Stefanik D, Sann J, Lam T et al (2008) Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate. Oral Dis 14:465–471CrossRefPubMedPubMedCentral

Merigo E, Manfredi M, Meleti M, Guidotti R, Ripasarti A, Zanzucchi E, D’Aleo P, Corradi D, Corcione L, Sesenna E, Ferrari S, Poli T, Bonaninil M, Vescovi P (2006) Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed 77(2):109–117PubMed

Re M, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575CrossRef

Rodan GA, Fleisch HA (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97(12):2692–2696CrossRefPubMedPubMedCentral

10.

Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12:6222–6230CrossRef

11.

Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ (2008) Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 42:848–860CrossRefPubMed

12.

Bartl R, von Tresckow E, Bartl C (2006) Bisphosphonat Manual. Springer, Berlin, Heidelberg, New York, S 43–93. ISBN 3‑540-25362‑9CrossRef

13.

Yamaguchi A, Kubo S, Matsunaga T, Shibahara T (2018) Report by the jaw bone disease project 1: concept, diagnosis and treatment of medication-related osteonecrosis of the jaw. Shikwa Gakuho 118:165–176

14.

Fleisch H (2002) The role of bisphosphonates in breast cancer: development of bisphosphonates. Breast Cancer Res 4(1):30–34CrossRefPubMed

15.

Mutschler E, Geisslinger G, Kroemer HK, Schäfer-Korting M (2001) Mutschler Arnzeimittelwirkungen, 8. Aufl. Wissenschaftliche Vertragsgesellschaft, Stuttgart, S 395–398

16.

International Task Force on Osteonecrosis of the Jaw (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:1CrossRef

17.

Aspenberg P (2006) Osteonecrosis: what does ist mean? One condition partly caused by bisphosphonates—or another one, preferably treated with them? Acta Orthop 77(5):693–694CrossRefPubMed

18.

Allen MR, Ruggiero SL (2009) Higher bone matrix density exists in only subset of patients with bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg 67:1373–1377CrossRefPubMed

19.

Sharma D, Ivanovski S, Slevin M et al (2013) Bisphosphonate-related osteonecrosis of the jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect. Vasc Cell 5:1–5CrossRefPubMedPubMedCentral

20.

Fedele S, Porter SR, D’Aiuto F et al (2010) Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 123:1060–1064CrossRefPubMed

21.

Ruggiero SL, Fantasia J, Carlson E (2006) Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:433–441CrossRefPubMed

22.

Fournier P, Boissier S, Filleur S et al (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538–6544PubMed

23.

Santini D, Vincenzi B, Dicuonzo G et al (2003) Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9:2893–2897PubMed

24.

Vincenzi B, Santini B, Dicuonzo G et al (2005) Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 25:144–151CrossRefPubMed

25.

Bamias A, Kastritis E, Bamia C et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580–8587. https://doi.org/10.1200/JCO.2005.02.8670 CrossRefPubMed

26.

Cartsos VM, Zhu S, Zavras A (2008) Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714.217 people. Am Dent Assoc 139:23–30CrossRef

27.

Lo JC, O’Ryan FS, Gordon NP et al (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonates exposure. Oral Maxillofac Surg 68:243–253CrossRef

28.

Felsenberg D (2006) Osteonecrosis of the jaw—a potential adverse effect of bisphosphonate treatment. Nat Clin Pract Endocrinol Metab 2:2662–2663CrossRef

29.

Khan AA et al (2011) Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. J Rheumatol 38:1396–1402CrossRefPubMed

30.

Lyles KW et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809CrossRefPubMed

31.

Powell D, Bowler C, Roberts T et al (2012) Incidence of serious side effects with intravenous bisphosphonates: a clinical audit. QJM 105:965–971CrossRefPubMed

32.

Tennis P, Rothman KJ, Bohn RL et al (2012) Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf 21:810–817CrossRefPubMed

33.

Grbic JT, Landesberg R, Lin SQ et al (2008) Incidence of osteonecrosis of the jaw in women with postmenosaumal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 139:32–40CrossRefPubMed

34.

Devogelaer JP, Brown JP, Burckhardt P et al (2007) Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int 18:1211–1218CrossRefPubMed

35.

Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, Farina L (2008) Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leukemia Lymphoma 49(11):2156–2162

36.

Klingelhoeffer Ch, Hoffmeister B (2012) Klinische Aspekte der Behandlung von Kiefernekrosen unter antiresorptiver Therapie. Osteologie 3:201–206

37.

Ferlito S, Puzzo S, Liardo C (2011) Preventive protocol for tooth extractions in patients treated with zoledronate: a case series. J Oral Maxillofac Surg 69(6):e1–e4CrossRefPubMed

38.

Ripamonti CI et al (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137–145CrossRefPubMed

39.

Dimopoulos MA et al (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117–120CrossRefPubMed

40.

Haidar A et al (2009) Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw. Scand J Urol Nephrol 43:442–444CrossRefPubMed

41.

Fehm T, Walter B, Wallwiener D (2010) Bisphosphonatbedingte Kieferosteonekrose. Empfehlungen zur Prävention und Therapie. Gynäkologe 43:517–520CrossRef

42.

Ruggiero SL, Dodson TB, Assael LA et al (2009) Task force on bisphosphonate-related osteonecrosis of the jaws. Am Assoc Oral Maxillofac Surg 69:2–12

43.

Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, Krikelis D, Terpos E (2006) Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 134:620–623CrossRefPubMed

44.

Corso A, Varettoni M, Zappasodi P, Klersy C, Mangiacavalli S, Pica G, Lazzarino M (2007) A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 21:1545CrossRefPubMed

45.

Wessel JH, Dodson TB, Zavras AI (2008) Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 66:625–631CrossRefPubMedPubMedCentral

46.

Chranovic BR, Albrektsson T, Wennerberg A (2015) Smoking and dental implants: a systematic review and meta-analysis. J Dent 43:487–498CrossRef

47.

Shanbhogue VV, Mitchell DM, Rosen CJ et al (2016) Type2 diabetes and the skeleton: new insights into sweet bones. Lancet Diabetes Endocrinol 4:159–173CrossRefPubMed

48.

Yahagi K, Kolodgie FD, Lutter C et al (2017) Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus. Arter Thromb Vasc Biol 37:191–204CrossRef

49.

Hua Y, Bi R, Zhang Y et al (2018) Different bone sites-specific response to diabetes rat models: bone density, histology and microarchitecture. PLoS ONE 13:e205503CrossRefPubMedPubMedCentral

50.

Vahtsevanos K et al (2009) Longitudinal cohortstudy of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356–5362CrossRefPubMed

51.

Felsenberg D, Lopez S, Gabbert T, Hoffmeister B (2012) Osteonekrose des Kiefers bei Osteoporosepatienten. Onkologie 3:207–212

52.

Felsenberg D, Hoffmeister B, Amling M et al (2006) Kiefernekrosen nach hoch dosierter Bisphosphonattherapie. Dtsch Zahnärztebl 103:3078–3080

53.

Shibahara T (2019) Antiresorptive agent-related osteonecrosis of the jaw (ARONJ): a twist of fate in the bone. Tohoku J Exp Med 247(2):75–86CrossRefPubMed

54.

Vandone AM et al (2012) Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. Ann Oncol 23:193–200CrossRefPubMed

55.

De Iuliis F, Taglieri L, Amoroso L, Vendittozzi S, Blasi L, Salerno G, Lanza R, Scarpa S (2014) Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates. Anticancer Research 34:2477–2480

56.

Bramati A, Girelli S, Farina G, Chiara M et al (2015) Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases. J Bone Miner Metab 33:119–124CrossRefPubMed

57.

Horn F (2015) Biochemie des Menschen. Thieme, Stuttgart, New YorkCrossRef

58.

Gilman’s G (2011) The pharmacological basis of therapeutics Bd. 12. Mc Graw Hill Medical, New York, Chicago, San Francisco

59.

Rogers TL, Holen I (2011) Tumour macrophages as potential targets of bisphosphonates. J Transl Med 9:177CrossRefPubMedPubMedCentral

60.

Diel I (2012) Kieferosteonekrosen in der Osteoonkologie. Osteolgie 3:194–200

Titel: Korreliert die Prävalenz der bisphosphonatassoziierten Kiefernekrosen mit der Einnahmedauer der Bisphosphonate bei Tumor- und Osteoporosepatienten?
Gesamtauswertung des Deutschen Kieferosteonekroseregisters
verfasst von: Cand. med. Dent. Niels Karberg, BA
Prof. Dr. med. Dieter Felsenberg
Publikationsdatum: 10.01.2020
Verlag: Springer Vienna
Erschienen in: Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen / Ausgabe 1/2020
Print ISSN: 2412-8260
Elektronische ISSN: 2412-8287
DOI: https://doi.org/10.1007/s41970-019-00094-6

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Mitteilungen des Magnesiumforum Bad Radkersburg

Editorial

Unterscheidung in verschiedene Patientensubgruppen bei Kreuzschmerz sinnvoll

News-Screen Rheumatologie

News-Screen Physikalische Medizin

News-Screen Osteologie